SRSF1介导细胞因子诱导的慢性髓性白血病伊马替尼敏感性受损
该研究通过RNA测序发现原代CD34+慢性期CML祖细胞中SRSF1表达因BCR-ABL1和细胞因子信号而升高。SRSF1过表达赋予未转化造血细胞细胞因子非依赖性并损害CML细胞对伊马替尼的敏感性,而敲低SRSF1可阻止外源性细胞因子降低伊马替尼敏感性。机制上PRKCH和PLCH1上调参与其中,且初诊时骨髓SRSF1极高水平与较差的临床TKI反应相关。
要点
- SRSF1在CD34+慢性期CML祖细胞中受BCR-ABL1和细胞因子信号上调。
- SRSF1过表达损害伊马替尼敏感性,敲低可阻断细胞因子的保护作用。
- 初诊骨髓SRSF1极高水平与较差TKI反应相关。
核心结论
- SRSF1水平在CD34+慢性期CML祖细胞中由细胞因子维持 despite 有效BCR-ABL1抑制,且升高水平促进伊马替尼反应受损。
- 数据支持SRSF1/PRKCH/PLCH1轴参与细胞因子诱导的CML伊马替尼敏感性受损。
研究设计与样本
- 使用RNA测序鉴定原代CD34+慢性期CML祖细胞与对照中差异表达的剪接因子。
- 功能实验包括SRSF1过表达和敲低,在未转化造血细胞和CML细胞中评估细胞因子非依赖性和伊马替尼敏感性。
主要发现
- SRSF1表达因BCR-ABL1和细胞因子介导的信号而增加。
- SRSF1过表达赋予未转化造血细胞细胞因子独立性并损害CML细胞伊马替尼敏感性。
- CD34+慢性期CML细胞中SRSF1敲低阻止外源性细胞因子降低伊马替尼敏感性。
- PRKCH和PLCH1因SRSF1水平升高而上调,并 contribute 至伊马替尼敏感性受损。
- 初诊CML患者骨髓中极高水平SRSF1与较差临床TKI反应相关。
临床怎么用
- SRSF1水平可能作为CML患者TKI反应异质性的生物标志物。
- 靶向SRSF1/PRKCH/PLCH1轴可能改善细胞因子介导的TKI耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic myeloid leukemia (CML) who are treated with tyrosine kinase inhibitors (TKIs) experience significant heterogeneity regarding depth and speed of responses. Factors intrinsic and extrinsic to CML cells contribute to response heterogeneity and TKI resistance. Among extrinsic factors, cytokine-mediated TKI resistance has been demonstrated in CML progenitors, but the underlying mechanisms remain obscure. Using RNA-sequencing, we identified differentially expressed splicing factors in primary CD34+ chronic phase (CP) CML progenitors and controls. We found SRSF1 expression to be increased as a result of both BCR-ABL1- and cytokine-mediated signaling. SRSF1 overexpression conferred cytokine independence to untransformed hematopoietic cells and impaired imatinib sensitivity in CML cells, while SRSF1 depletion in CD34+ CP CML cells prevented the ability of extrinsic cytokines to decrease imatinib sensitivity. Mechanistically, PRKCH and PLCH1 were upregulated by elevated SRSF1 levels, and contributed to impaired imatinib sensitivity. Importantly, very high SRSF1 levels in the bone marrow of CML patients at presentation correlated with poorer clinical TKI responses. In summary, we find SRSF1 levels to be maintained in CD34+ CP CML progenitors by cytokines despite effective BCR-ABL1 inhibition, and that elevated levels promote impaired imatinib responses. Together, our data support an SRSF1/PRKCH/PLCH1 axis in contributing to cytokine-induced impaired imatinib sensitivity in CML.
引用
- Sinnakannu JR, Lee KL, Cheng S, et al. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. Leukemia. 2020. PMID: 32051529. doi:10.1038/s41375-020-0732-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。